Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of Lilly's drug, Retevmo. Both are RET inhibitors.
The company will present a poster on pralsetinib, its RET inhibitor, which some analysts wrote they view as being "interchangeable" with Lilly's Retevmo, which received accelerated FDA approval last week.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer and thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.